|
|
|
|
|
|
|
Mon T W Th F |
|
6 July, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There have been 23 new drugs approved through the first six months of 2026, Zachary Brennan reports. That's kept pace with the rate of new approvals in the past few years, despite heavy FDA staff cuts. |
|
|
|
Lydia Ramsey Pflanzer |
Deputy Editor, Endpoints News
|
|
|
|
|
|
|
by Zachary Brennan
|
There's an answer emerging on the multibillion-dollar question of whether the Trump administration's gutting of FDA staff in April 2025 would slow down drug approvals... | |
|
|
|
|
|
|
by Nicole DeFeudis
|
A proposed rule would cut the rates by which Medicare pays hospitals for 340B drugs by more than a third, reviving a similar policy introduced... | |
|
|
|
|
|
|
|
|
by Max Bayer
|
Acting FDA CDER director Michael Davis has promoted a longtime FDA staffer as an acting deputy director at the drug center. Lisa Yanoff, an agency... | |
|
|
|
|
|
|
by Max Gelman
|
While Americans geared up for the July 4 holiday, Bristol Myers Squibb laid out how a confirmatory trial for its drug Krazati failed in colorectal... | |
|
|
|
 |
|
Gerald Joyce, Salk Institute president (Credit: Salk Institute) |
|
|
|
by Andrew Dunn
|
SAN DIEGO — From the president’s office at the Salk Institute, Gerald Joyce has a quintessential California view of hang gliders soaring over the Pacific Ocean... | |
|
|
|
|
|
|
by Elizabeth Cairns
|
Monday’s deal between Otsuka’s subsidiary Astex and Roche’s subsidiary Genentech is of interest not because it is big |
|
|
